New Zealand King Salmon Investments Ltd (ASX:NZK)
A$ 0.18 (0%) Market Cap: 101.32 Mil Enterprise Value: 75.13 Mil PE Ratio: 0 PB Ratio: 0.59 GF Score: 63/100

Half Year 2025 New Zealand King Salmon Investments Ltd Earnings Call Transcript

Sep 23, 2024 / 10:00PM GMT
Release Date Price: A$0.24 (-2.04%)

Key Points

Positve
  • Pro-forma EBITDA increased by 26% to $13.5 million compared to $10.7 million in the prior year.
  • Revenue increased by 11% to $101.7 million for the half year.
  • Net cash on hand remains strong at $32.5 million.
  • Ongoing investments in R&D to improve fish health, including thermotolerance work and vaccine developments.
  • Blue Endeavor pilot project is progressing well, with infrastructure and fish for the pilot already in place.
Negative
  • Net profit decreased to $6.0 million from $10.6 million in the prior year.
  • Higher mortality rates due to increased biomass on farms.
  • Challenges with early runting affecting fish performance and harvest volumes.
  • Increased corporate costs due to capability enhancements and compliance requirements.
  • Feed pricing remains highly volatile due to global commodity prices and geopolitical issues.
Operator

(audio in progress) New Zealand King Salmon Investments Limited half year results announcements. (Operator Instructions) I would now like to hand the conference over to Mr. Carl Carrington, Chief Executive Officer. Please go ahead.

Carl Carrington
New Zealand King Salmon Investments Ltd - Chief Executive Officer

Good morning, everyone. Welcome to the New Zealand King Salmon half year results. This morning, I'm going to be presenting a presentation in conjunction Ben Rodgers, CFO; Graeme Tregidga, Chief Commercial Officer; and Grant Lovell, GM of Aquaculture.

So firstly, I'm going to take you through an exec summary of the results, starting with the GAAP. Net profit for the first half $6.0 million. That compares to first half last year of $10.6 million. Compared to the prior comparable period, the GAAP results have been impacted by non-cash adjustments relating to biological inventory, which was a loss of $3.6 million and a smaller contribution from the unwind of earlier close out ForEx contracts which was $2.6 million compared to $3.6 million in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot